Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthmaApproval based on global phase 3 program ...

Dupixent had the most impressions and largest impressions share of voice (SOV) among Rx and over-the-counter (OTC) brands in March, according to data released by iSpot.tv Monday evening. This is a ...

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung ...

Sanofi and Regeneron’s immunology blockbuster Dupixent had been on a mini streak as king of the pharma airwaves but was knocked off its perch in June by AbbVie’s competing drug Rinvoq. That’s ...

For the first time in 2024, Dupixent has been named a top monthly Rx and over-the-counter (OTC) pharma brand. According to data released by iSpot.tv on Wednesday morning, the eczema and asthma ...

Most people with asthma are able to control their symptoms by using inhaled medicines each day. But for some people with severe asthma, inhaled medicines are not enough to keep symptoms under control.

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. The Food and Drug Administration on Friday approved a ...

Sanofi’s stock dropped in the wake of data from its Phase III trial of atopic dermatitis (AD) candidate amlitelimab, which had been touted as a potential successor to Dupixent. While the Phase III ...

Most people with a condition known as chronic rhinosinusitis with nasal polyps (CRSwNP) are able to control their symptoms by using medicines that are sprayed into the nose or taken by mouth. But some ...

Dupixent (dupilumab) has been a breakthrough treatment for people with severe eczema, asthma, and other inflammatory conditions. For many, it has provided relief when other therapies failed. However, ...